• Bempedoic acid combinations show promise for LDL lowering

    5 days ago - By Healio

    A phase 2 study of bempedoic acid combined with ezetimibe plus atorvastatin showed LDL reduction, and an additional phase 2 study of bempedoic acid combined with a PCSK9 inhibitor has been initiated, according to press releases from Esperion Therapeutics. The combination of bempedoic acid/ezetimibe plus atorvastatin reduced LDL cholesterol by 64% compared with placebo. In the treatment group, 95% of patients achieved at least 50% LDL reduction and 90% achieved LDL levels of less than 70 mg/dL.
    Read more ...